Depletion of RIPK4 parallels higher malignancy potential in cutaneous squamous cell carcinoma

Jing Xu1, Dongping Wu2, Bicheng Zhang1

  • 1Department of Radiation Oncology, The Second Affiliated Hospital and Cancer Institute (National Ministry of Education Key Laboratory of Cancer Prevention and Intervention), Zhejiang University School of Medicine, Hangzhou, China.

Peerj
|February 21, 2022
PubMed
Abstract

Insights

Receptor-interacting protein kinase 4 (RIPK4) silencing increases skin squamous cell carcinoma (SCC) malignancy but does not affect radiosensitivity. Further research into RIPK4's role may offer a prognostic biomarker for skin SCC.

Area of Science:

  • Oncology
  • Dermatology
  • Molecular Biology

Background:

  • Receptor-interacting protein kinase 4 (RIPK4) regulates epidermal differentiation, inflammation, and wound repair.
  • The role of RIPK4 in skin squamous cell carcinoma (SCC) tumorigenesis and its impact on radiosensitivity are largely unknown.
  • Understanding RIPK4's mechanism in skin SCC is crucial for identifying potential biomarkers.

Purpose of the Study:

  • To investigate the effect of RIPK4 silencing on the malignancy and radiosensitivity of human skin SCC.
  • To explore the influence of RIPK4 on the Raf/MEK/ERK signaling pathway in skin SCC.
  • To determine if RIPK4 expression levels correlate with radiosensitivity in skin SCC.

Main Methods:

  • Human skin SCC cell line (A431) was transfected with RIPK4-targeting siRNAs.
  • Western blotting assessed RIPK4 and Raf/MEK/ERK pathway protein expression.
  • Cells were subjected to irradiation, followed by assays for proliferation, colony formation, migration, invasion, cell cycle, and apoptosis.

Main Results:

  • RIPK4 silencing significantly decreased RIPK4 protein expression.
  • RIPK4 knockdown enhanced A431 cell proliferation, colony formation, migration, and invasion.
  • RIPK4 silencing did not significantly affect cell cycle or apoptosis and did not alter radiosensitivity in vitro.
  • The Raf/MEK/ERK pathway was not affected by RIPK4 knockdown in this study.

Conclusions:

  • RIPK4 depletion correlates with increased malignancy potential in cutaneous SCC, independent of radiosensitivity.
  • This study is the first to report on RIPK4's effects on the Raf/MEK/ERK pathway and radiosensitivity in cutaneous SCC.
  • RIPK4 may serve as a potential biomarker for skin SCC prognosis and treatment strategies.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.2K
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
3.8K